Publications by authors named "Lucio Crinò"

100Publications

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting.

Cancers (Basel) 2020 Apr 8;12(4). Epub 2020 Apr 8.

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12040915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226231PMC
April 2020

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.

Front Oncol 2019 24;9:1519. Epub 2020 Jan 24.

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.01519DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992646PMC
January 2020

New generation anaplastic lymphoma kinase inhibitors.

Transl Lung Cancer Res 2019 Nov;8(Suppl 3):S280-S289

Thoracic Oncology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2019.09.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894988PMC
November 2019

Role of liquid biopsy in oncogene-addicted non-small cell lung cancer.

Transl Lung Cancer Res 2019 Nov;8(Suppl 3):S265-S279

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2019.09.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894991PMC
November 2019

Molecular targeted therapies in non-small cell lung cancer: where we are.

Transl Lung Cancer Res 2019 Nov;8(Suppl 3):S222-S223

Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Maroncelli, Meldola (FC), Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2019.11.13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894989PMC
November 2019

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer.

J Oncol 2019 19;2019:7475364. Epub 2019 Aug 19.

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7475364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721259PMC
August 2019

Antitumor activity of larotrectinib in tumors harboring gene fusions: a short review on the current evidence.

Onco Targets Ther 2019 30;12:3171-3179. Epub 2019 Apr 30.

Department of Biomedical and Biotechnological Sciences, Pathology and Oncology Section, University of Catania, Catania, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S177051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503327PMC
April 2019

Targeting RET-rearranged non-small-cell lung cancer: future prospects.

Lung Cancer (Auckl) 2019 20;10:27-36. Epub 2019 Mar 20.

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/LCTT.S192830DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433115PMC
March 2019

Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.

Biol Rev Camb Philos Soc 2018 11 19;93(4):1735-1746. Epub 2018 Apr 19.

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/brv.12416DOI Listing
November 2018

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.

Med Oncol 2018 Apr 17;35(5):72. Epub 2018 Apr 17.

Department of Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Piazzale L. Severi n. 1, 06132, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-018-1133-4DOI Listing
April 2018

Perspectives in small cell lung cancer: is something moving?

Transl Lung Cancer Res 2017 Dec;6(Suppl 1):S47-S50

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2017.10.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750163PMC
December 2017

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

J Clin Oncol 2017 Dec 12;35(35):3924-3933. Epub 2017 Oct 12.

Leora Horn, Vanderbilt-Ingram Cancer Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Everett E. Vokes, University of Chicago, Chicago, IL; Esther Holgado, Hospital De Madrid, Norte Sanchinarro, Madrid; Enriqueta Felip, Hospital Universitari Vall d'Hebron, Barcelona; Luis Paz-Ares, Hospital Universitario Virgen Del Rocio, Seville, Spain; Neal Ready, Duke University Medical Center, Durham, NC; Martin Steins, Thoraxklinik-Heidelberg gGmbH, Heidelberg; Martin Kohlhäeufl, Robert-Bosch-Krankenhaus, Stuttgart; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Wilfried E.E. Eberhardt, University Hospital and Ruhrlandclinic, University of Duisburg-Essen, Essen, Germany; Elena Poddubskaya, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Adam Pluzanski, Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie, Warsaw, Poland; Karen L. Reckamp, City of Hope, Duarte, CA; Marco A. Burgio and Lucio Crinò, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori, Meldola, Italy; David Waterhouse, Oncology Hematology Care (OHC)/US Oncology, Cincinnati, OH; Fabrice Barlesi, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Marseille; Jérôme Fayette, Léon Bérard, Lyon, France; Scott Antonia, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Oscar Arrieta, Instituto Nacional De Cancerologia, Mexico City, Mexico; Naiyer Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; William J. Geese, Ang Li, Anne Blackwood-Chirchir, and Diane Healey, Bristol-Myers Squibb, Princeton, NJ; and Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.3062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075826PMC
December 2017

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Cancer Treat Rev 2017 Apr 30;55:181-189. Epub 2017 Mar 30.

University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.006DOI Listing
April 2017

Optimal management of ALK-positive NSCLC progressing on crizotinib.

Lung Cancer 2017 04 6;106:58-66. Epub 2017 Feb 6.

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002173003
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2017.02.003DOI Listing
April 2017

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 12 31;34(34):4079-4085. Epub 2016 Oct 31.

Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Alice T. Shaw, Massachusetts General Hospital; Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; D. Ross Camidge, University of Colorado Cancer Center, Denver, CO; Alberto Chiappori, Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Sai-Hong Ignatius Ou, University of California at Irvine, Orange, CA; Luigi De Petris, Karolinska Institutet, Stockholm, Sweden; Dong-Wan Kim, Seoul National University Hospital, Seoul; Ji-Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea; Denis L. Moro-Sibilot, Service de Pneumologie; Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble; Eric Dansin, Centre Oscar Lambret, Lille, France; Lucio Crino, Santa Maria della Misericordia Hospital, Perugia; Tommaso De Pas, European Institute of Oncology, Milan, Italy; Antje Tessmer, Evangelische Lungenklinik Berlin, Berlin, Germany; James Chih-Hsin Yang, Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University, Taipei, Taiwan; and Walter Bordogna, Sophie Golding, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4639DOI Listing
December 2016

Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland.

Tumori 2016 Nov 11;102(Suppl. 2). Epub 2016 Nov 11.

Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia - Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5301/tj.5000514DOI Listing
November 2016

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

J Clin Oncol 2016 08 18;34(24):2866-73. Epub 2016 Jul 18.

Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.5936
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.5936DOI Listing
August 2016

Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.

J Neurooncol 2016 09 20;129(2):355-61. Epub 2016 Jun 20.

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, via Dottori, 1, 06156, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-016-2184-zDOI Listing
September 2016

Targeting EGFR and ALK in NSCLC: current evidence and future perspective.

Lung Cancer Manag 2016 Jun 23;5(2):79-90. Epub 2016 Jun 23.

Department of Medical Oncology, S Maria della Misericordia Hospital, Perugia/Italy.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/lmt-2016-0005
Publisher Site
http://dx.doi.org/10.2217/lmt-2016-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310340PMC
June 2016

Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.

Clin Drug Investig 2016 Aug;36(8):683-6

Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, via Dottori 1, 06156, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40261-016-0411-1DOI Listing
August 2016

Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy.

Med Oncol 2016 Feb 19;33(2):18. Epub 2016 Jan 19.

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Via Dottori 1, 06156, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-016-0731-2DOI Listing
February 2016

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.

Expert Rev Respir Med 2016 17;10(1):53-68. Epub 2015 Nov 17.

a Medical Oncology , Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia , Perugia , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17476348.2016.1115349DOI Listing
May 2016

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.

Expert Opin Pharmacother 2015 6;16(17):2601-13. Epub 2015 Oct 6.

a 1 Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia , Perugia, Italy +39 07 55 78 41 85 ; +39 07 55 78 41 84 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2015.1094056DOI Listing
June 2016

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

N Engl J Med 2015 Oct 27;373(17):1627-39. Epub 2015 Sep 27.

From the Fox Chase Cancer Center, Philadelphia (H.B.); Hospital Universitario Virgen del Rocio, Seville (L.P.-A.), Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.), and Hospital de Madrid, Norte Sanchinarro, Madrid (E.H.) - all in Spain; Vanderbilt-Ingram Cancer Center (L.H.), and Sarah Cannon Research Institute and Tennessee Oncology (D.R.S.) - both in Nashville; Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) and Robert-Bosch-Krankenhaus Stuttgart, Gerlingen (M.K.) - both in Germany; Duke University Medical Center, Durham, NC (N.E.R.); University of Washington, Seattle (L.Q.C.); University of Chicago Medicine and Biological Sciences, Chicago (E.E.V.); Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.), Centre Léon Bérard, Lyon (J.F.), and Centre Hospitalier Universitaire de Rennes, Rennes (H.L.) - all in France; Instituto Nacional de Cancerologia, Mexico City (O.A.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Forlì-Cesena (M.A.B.), and Ospedale di Perugia, Perugia (L.C.) - both in Italy; N.N. Blokhin Russian Cancer Research Center, Moscow (E.P.); University of Texas Southwestern Medical Center, Dallas (D.E.G.); Yale Comprehensive Cancer Center, New Haven, CT (S.N.G.); Memorial Sloan Kettering Cancer Center, New York (C.M.R., N.R.); University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (S.J.A.); Bristol-Myers Squibb, Princeton, NJ (C.D., C.T.H., F.G.F.); and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.R.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1507643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705936PMC
October 2015

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

J Clin Oncol 2015 Dec 31;33(34):4007-14. Epub 2015 Aug 31.

Karen Kelly, University of California, Davis, Comprehensive Cancer Center, Sacramento, CA; Nasser K. Altorki, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY; Wilfried E.E. Eberhardt, University Hospital Essen, Essen, Germany; Mary E.R. O'Brien, Royal Marsden Hospital, London, United Kingdom; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Lucio Crinò, Ospedale S. Maria della Misericordia, Perugia, Italy; Chun-Ming Tsai, Taipei General Hospital and National Yang-Ming University, Taipei, Taiwan; Joo-Hang Kim, Yonsei University Health System, Seoul; Eun Kyung Cho, Gachon University, Incheon, Korea; Philip C. Hoffman, The University of Chicago Medical Center, Chicago; Jiuzhou Wang and Margaret A. Foley, Astellas Pharma, Northbrook, IL; Sergey V. Orlov, I.P. Pavlov Medical University, St Petersburg, Russia; Piotr Serwatowski, Specjalistyczny Szpital, Sokolowskiego, Szczecin, Poland; Julie D. Horan, Novella Clinical, Boulder, CO; and Frances A. Shepherd, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/08/31/JCO.2015.61
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.8918
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.8918DOI Listing
December 2015

Dyskerin and TERC expression may condition survival in lung cancer patients.

Oncotarget 2015 Aug;6(25):21755-60

Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, I-40138, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.4580DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673301PMC
August 2015

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.

J Thorac Oncol 2015 Oct;10(10):1437-43

*Center of Predictive Molecular Medicine, Ce.S.I., G. D'Annunzio University-Foundation, Chieti, Italy; †Medical Scientific Affairs Department, Roche Molecular Systems, Pleasanton, California; ‡Oncological and Cardiovascular Molecular Medicine Unit, Ce.S.I., G. D'Annunzio University-Foundation, Chieti, Italy; §Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy; ‖Department of Medical Oncology, S. Maria della Misericordia Hospital, Perugia, Italy; ¶Department of Medical Oncology, Bellaria-Maggiore Hospital, Azienda USL of Bologna, Bologna, Italy; #Unit of Pneumology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; **Ospedale Civile di Pescara, Pescara, Italy; ††Ospedale Civile di Sulmona, Sulmona, Italy; ‡‡Department of Medical Oncology, Consorzio Interuniversitario Nazionale per la Bio-Oncologia, G. d'Annunzio University, Chieti, Italy; §§Department of Oncology-Haematology, Humanitas Cancer Center, IRCCS, Milan, Italy; and ‖‖Perugia University Medical School, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000643DOI Listing
October 2015

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

N Engl J Med 2015 Jul 31;373(2):123-35. Epub 2015 May 31.

From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.B.); the City of Hope Comprehensive Cancer Center, Duarte, CA (K.L.R.); the Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam (P.B.), Erasmus MC Cancer Institute, Rotterdam (J.G.A.), and Ziekenhuis Amphia, Breda (J.G.A.) - all in the Netherlands; the University Hospital of Perugia, Perugia (L.C.), and the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (M.C.G.) - both in Italy; the Department of Medical Oncology, West German Cancer Center, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen (W.E.E.E.), the Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.), and the LungenClinic Grosshansdorf, Grosshansdorf (M.R.) - all in Germany; the N.N. Blokhin Russian Cancer Research Center, Moscow (E.P.); the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (S.A.); the Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland (A.P.); the University of Chicago Medicine and Biological Sciences, Chicago (E.E.V.); the Hospital Madrid Norte Sanchinarro (E.H.), the Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.), and the Hospital Universitario Virgen Del Rocío, Seville (L.P.-A.) - all in Spain; Oncology Hematology Care, Cincinnati (D.W.); the Duke University Medical Center, Durham, NC (N.R.); Massachusetts General Hospital, Boston (J.G.); Centro Internacional de Estudios Clinicos, Santiago, Chile (O.A.F.); Nemocnice Na Bulovce, Prague, Czech Republic (L.H.); Bristol-Myers Squibb, Princeton, NJ (C.B., C.T.H., B.L.); and the Sarah Cannon Research Institute and Tennessee Oncology, Nashville (D.R.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1504627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681400PMC
July 2015

MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Am J Clin Oncol 2015 Apr;38(2):152-8

*Department of Medical Oncology, S. Maria della Misericordia Hospital Departments of †Electronic and Information Engineering ‡Thoracic Surgery §Institute of Pathological Anatomy and Histology, University of Perugia, Perugia, Italy ∥Department of Medicine/Medical Oncology, University of Colorado Cancer Center, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607281PMC
April 2015

Pharmacokinetics of trastuzumab in haemodialysis.

Breast J 2015 May-Jun;21(3):329-31. Epub 2015 Mar 19.

Department of Medical Oncology, Ospedale Sacro Cuore Don Calabria, Negrar-Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.12407DOI Listing
May 2016

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

J Clin Oncol 2015 Mar 9;33(9):992-9. Epub 2015 Feb 9.

Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/02/03/JCO.2014.58
Web Search
http://jco.ascopubs.org/content/early/2015/02/03/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.3302
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.3302DOI Listing
March 2015

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

J Clin Oncol 2015 Jun 26;33(17):1881-8. Epub 2015 Jan 26.

Daniel B. Costa, Beth Israel Deaconess Medical Center, Harvard Medical School; Alice T. Shaw, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Sai-Hong I. Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Irvine; S. Martin Shreeve, Paulina Selaru, and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Gregory J. Riely, Memorial Sloan-Kettering Cancer Center; Patrick Schnell, Pfizer Oncology, New York, NY; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea; Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China; Anna Polli, Pfizer Oncology, Milan; Lucio Crinò, Perugia University Medical School, Perugia, Italy; Robin Wiltshire, Pfizer Oncology, Tadworth, United Kingdom; and D. Ross Camidge, University of Colorado Denver, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451171PMC
June 2015

Perspectives of novel imaging techniques for staging, therapy response assessment, and monitoring of surveillance in lung cancer: summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop.

J Thorac Oncol 2015 Feb;10(2):237-49

*Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; †Division of Thoracic Surgery, Royal Brompton Hospital, Imperial College London, London, United Kingdom; ‡Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; §Department of Medicine I, Medical University of Vienna, Vienna, Austria; ║Division of Thoracic Surgery, University Hospital of Zurich, Zurich, Switzerland; ¶Medical Oncology Division, Department of Oncology, University Hospital Perugia, Perugia, Italy; #Lung Cancer Research, University of Leicester & Leicester University Hospitals, Leicester, United Kingdom; **Department of Radiology, General Hospital Celle, Celle, Germany; ††Department of Thoracic and Vascular Surgery, Hôpital Tenon, University of Paris VI, Paris, France; ‡‡Department of Surgery/Thoracic Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; §§Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; ║║Department of Radiation Oncology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands; ¶¶Department of Pneumology, Respiratory Oncology Unit and Trial Unit, University Hospital KU Leuven, Leuven, Belgium; ##Clinical Competence Center Oncology, Siemens AG, Erlangen, Germany; ***Institute of Clinical Radiology and Nuclear Medicine/Department of Molecular Imaging & Radiopharmacy, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; †††Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000412DOI Listing
February 2015

Future options for ALK-positive non-small cell lung cancer.

Lung Cancer 2015 Mar 3;87(3):211-9. Epub 2015 Jan 3.

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.12.017DOI Listing
March 2015

Non-coding RNAs in lung cancer.

Oncoscience 2014 15;1(11):674-705. Epub 2014 Nov 15.

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278269PMC
http://dx.doi.org/10.18632/oncoscience.98DOI Listing
January 2015

Postsurgical follow-up is always necessary in bronchial carcinoid.

Ann Thorac Surg 2014 Sep;98(3):1143-4

Multidisciplinary Neuroendocrine Tumors Center, European Neuroendocrine Tumor Society Center of Excellence, Umbria Regional Cancer Network, Via E. dal Pozzo, 06126Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2014.04.020DOI Listing
September 2014

ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.

J Thorac Oncol 2014 Oct;9(10):1470-6

*Center of Predictive Molecular Medicine, Center of Excellence on Aging, University-Foundation, Chieti, Italy; †Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; ‡Division of Anatomic Pathology, San Luigi Hospital and University of Turin, Orbassano, Italy; §Pathology Department, Policlinico di Modena, Modena, Italy; ‖Diagnostic and Laboratory Medicine, INT-Fondazione "G.Pascale", Naples, Italy; ¶Medical Oncology Unit, University Hospital, Parma, Italy; #Department of Medical Oncology, Perugia Hospital, Perugia, Italy; **Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy; ††Department of Human Pathology and Oncology, University of Florence, Florence, Italy; ‡‡Pathology Department, Casa di Cura San Pio X and I.R.C.C.S. Policlinico San Donato, Milano, Italy; §§Thoracic Oncology Unit, University of Torino, San Luigi Hospital, Torino, Italy; ‖‖Cell Biology and Biotherapy Unit, INT-Fondazione "G.Pascale", Naples, Italy; and ¶¶Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000280DOI Listing
October 2014

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.

PLoS One 2014 19;9(8):e103883. Epub 2014 Aug 19.

Center of Predictive Molecular Medicine, Center of Excellence on Aging, University-Foundation, Chieti, Italy; Oncological and Cardiovascular Molecular Medicine Unit, Center of Excellence on Aging, University-Foundation, Chieti, Italy.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103883PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138040PMC
October 2015

Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.

J Thorac Oncol 2014 May;9(5):733-7

*Division of Medical Oncology, "SG Moscati" Hospital, Avellino, Italy; †Department of Oncology, University of Turin, AOU San Luigi Orbassano, Turin, Italy; ‡Medical Oncology 1, "Fondazione IRCCS Istituto Nazionale dei Tumori", Milan, Italy; §Department of Oncology, San Paolo Hospital, Milan, Italy; ‖Second Medical Oncology Unit, "Istituto Oncologico Veneto", Padua, Italy; ¶European Institute of Oncology, Milan, Italy; #Department of Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola (FC), Italy; **Division of Medical Oncology, S. Maria della Misericordia Hospital, Perugia, Italy; ††Lung Cancer Unit, National Institute for Cancer Research, Genoa, Italy; ‡‡Medical Oncology Department, Santa Chiara Hospital, Trento, Italy; §§Medical Oncology Unit, San Vincenzo Hospital, Taormina, Catania, Italy; ‖‖Oncology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy; ¶¶Medical Oncology Department, AUSL Bologna, Italy; ##Medical Oncology Unit, "Giovanni Paolo II" National Cancer Centre, Bari, Italy; ***Department of Oncology, Azienda Ospedaliera Treviglio, Treviglio (BG), Italy; †††Department of Oncology, University Hospital of Udine, Udine, Italy; ‡‡‡Department of Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy; §§§AstraZeneca, Basiglio (MI), Italy; ‖‖‖LB Research, Cantù (CO), Italy; and ¶¶¶Medical Oncology, Second University of Naples, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000120DOI Listing
May 2014

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.

Eur Respir Rev 2014 Mar;23(131):79-91

Division of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/09059180.00008913DOI Listing
March 2014